Asthma remains one of the most pervasive chronic diseases affecting children worldwide, manifesting primarily through symptoms such as shortness of breath, persistent coughing, and repeated respiratory infections. Despite decades of research, the etiology of childhood asthma is incompletely understood. A pioneering study conducted by researchers affiliated with the University of Copenhagen and the Copenhagen Prospective Studies on Asthma in Childhood (COPSAC) at Herlev and Gentofte Hospital brings to light a potentially critical factor: the presence of the fatty acid molecule 12-hydroxyeicosatetraenoic acid (12-HETE) in maternal blood during pregnancy appears strongly associated with the child’s risk of developing asthma.
This extensive longitudinal study monitored several hundred mother-child pairs over a decade, measuring maternal 12-HETE levels at approximately the 24th week of gestation and closely tracking respiratory health outcomes in their offspring. Strikingly, researchers observed a 62 percent increase in the incidence of childhood asthma among children whose mothers exhibited non-measurable levels of 12-HETE during pregnancy compared to those with detectable levels. While the study explicitly refrains from asserting causality, this robust statistical association advances the hypothesis that 12-HETE could serve as a biomarker reflecting in utero environmental and immunological factors shaping susceptibility to asthma.
The biological mechanisms underpinning this association implicate 12-HETE in the early immunological programming and maturation of the fetal immune system. By the time infants reach one month of age, children born to mothers lacking 12-HETE display conspicuously altered airway bacterial profiles and perturbed immune responses—conditions known to predispose individuals to respiratory infections and subsequent asthma development. It is surmised that insufficient 12-HETE exposure in utero compromises fetal immune system development, leading to dysbiosis in the pulmonary microbiome and heightened vulnerability to respiratory pathogens.
In addition to these observational findings, the research team leveraged a randomized controlled trial nested within the Danish cohort to examine interactions between prenatal omega-3 fatty acid supplementation and maternal 12-HETE status. Omega-3, commonly obtained from fish oil, has been recognized for its anti-inflammatory properties and previous evidence suggested potential protective effects against childhood asthma. Intriguingly, this study discerned that the protective effect of omega-3 supplementation was confined to mothers with measurable 12-HETE levels. Among these mothers, omega-3 supplementation correlated with a compelling 58 percent reduction in early childhood asthma incidence compared to placebo. Conversely, in mothers lacking detectable 12-HETE, omega-3 intake exhibited no discernible impact on asthma outcomes.
These insights elucidate a critical nuance in prenatal nutritional interventions: the efficacy of omega-3 supplementation in mitigating asthma risk may hinge on the maternal 12-HETE milieu. This raises the provocative possibility of stratifying pregnant women based on 12-HETE profiles to personalize preventive strategies against asthma, eschewing the “one-size-fits-all” supplementation model in favor of targeted approaches that maximize benefit and resource allocation.
The research capitalized on data from two major mother-child cohorts, the Danish COPSAC2010 cohort comprising 738 mothers and 700 children, and the American Vitamin D Antenatal Asthma Reduction Trial (VDAART) cohort with 881 women and 810 children. Both cohorts facilitated rigorous epidemiological validation, bolstering the reproducibility and generalizability of findings across different populations and healthcare systems. The consistent replication of the association between maternal 12-HETE and childhood asthma across these cohorts underpins the robustness of the observed relationship.
Methodologically, the study combined state-of-the-art analytical chemistry techniques to quantify 12-HETE concentrations with high-resolution microbiome sequencing and immunophenotyping in infants’ airway samples. These multi-omic approaches enabled comprehensive profiling of the complex interactions between maternal fatty acid metabolism, fetal immune system development, and early-life microbial colonization, painting a nuanced portrait of asthma pathogenesis beginning in utero.
Despite these compelling advances, the authors prudently acknowledge that their study does not establish a direct causal link between 12-HETE deficiency and asthma onset. The intricate interplay of genetic predisposition, environmental exposures, and additional maternal-fetal biochemical mediators necessitates further mechanistic studies to unravel causal pathways. Moreover, before clinical translation, standardized biomarkers and threshold values must be defined to guide interventions effectively.
This study heralds a paradigm shift in understanding prenatal determinants of childhood asthma, highlighting the potential of 12-HETE as a prognostic biomarker and a modulator of prenatal supplement efficacy. Future research aimed at elucidating the metabolic pathways regulating 12-HETE production and its immunomodulatory functions could unlock novel therapeutic and preventive avenues. Ultimately, this could pave the way for precision medicine in asthma prevention, tailoring strategies to individual maternal-fetal profiles to curb the global burden of this debilitating pediatric disease.
As asthma continues to impose significant morbidity on children and strain healthcare systems worldwide, insights from this Danish-American collaborative effort mark a crucial step toward deciphering the earliest biological origins of asthma. With 12-HETE at the forefront, the prospect of early identification and targeted intervention holds promise to transform pediatric respiratory health paradigms fundamentally.
Subject of Research: The association of maternal 12-hydroxyeicosatetraenoic acid (12-HETE) levels during pregnancy with the risk of childhood asthma and the impact on responses to prenatal omega-3 supplementation.
Article Title: Maternal 12-HETE is associated with childhood asthma and the responses to prenatal omega-3 supplementation
News Publication Date: March 17, 2026
Web References: https://www.sciencedirect.com/science/article/pii/S2666379126001060
Keywords: Childhood asthma, 12-HETE, fatty acids, omega-3 supplementation, prenatal biomarkers, immune system maturation, pulmonary microbiome, respiratory infections, prenatal nutrition, COPSAC cohort, VDAART cohort, personalized prevention
